Renal Cancer News and Research

RSS

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Genomic Health, Inc. today reported financial results and business progress for the quarter ended March 31, 2010.

6 May 2010

EORTC 30904 study: Conservative surgery not inferior to radical renal surgery

The latest results from the European Organisation for Research and Treatment of Cancer (EORTC) 30904 study were presented in a plenary session today at the Anniversary European Association of Urology Congress in Barcelona, which showed that conservative surgery is not inferior to radical renal surgery or nephrectomy.

19 Apr 2010

Obesity could lead to renal cell cancer: BJUI

Being obese could lead to a greater risk of developing the most common form of renal cell cancer, according to research in the January issue of the UK-based urology journal BJUI.

13 Jan 2010

Obese patients at greater risk of developing renal cell cancer

Being obese could lead to a greater risk of developing the most common form of renal cell cancer, according to research in the January issue of the UK-based urology journal BJUI.

12 Jan 2010

Mutations in genome regulation machinery identified in clear cell renal cell carcinoma

In a new study, scientists have searched for mutations in the gene regions of more than 100 kidney cancer samples, the largest number of samples from a single tumour type to be sequenced to date.

7 Jan 2010

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

Webinar: Latest updates on percutaneous and transcatheter treatment of liver, kidney and lung tumor ablation

Registration is now open for the Society of Interventional Radiology's "Image-guided Interventional Oncology (IO) Therapies" Webinar, which will provide the latest updates on percutaneous and transcatheter treatment of liver tumors, kidney tumor ablation and lung tumor ablation.

7 Nov 2009

New software programs improve the cancer biomarker identification process

caCORRECT and omniBioMarker programs earn silver-level compatibility certification from NIH/National Cancer Institute's cancer Bioinformatics Grid

19 Aug 2009

New immune therapy for kidney cancer tested

Researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial to evaluate whether the standard treatment for a common form of kidney cancer works better by itself or when combined with a certain type of blood cell that comes from a patient’s relative. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

14 Aug 2009

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.

31 May 2009

Seattle Genetics presents new data on antibody-drug conjugate

Seattle Genetics, Inc. has announced that data from its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-75, were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO. Preclinical data with SGN-35 further elucidate its mechanism of action and demonstrate its superior antitumor activity in lymphoma compared with non-targeted agents. In addition, data with SGN-75 indicate its therapeutic potential in multiple types of solid tumors.

22 Apr 2009

Discovery of new cancer gene

Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes.

29 Mar 2009

$Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma$

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.

10 Dec 2008

Scientists pinpoint two new risk factors for Wilms tumour

Scientists at The Institute of Cancer Research have made significant progress in pinpointing two new risk factors associated with the most common childhood kidney cancer, known as Wilms tumour.

1 Dec 2008

Cancer drug bevacizumab linked to significantly increased risk of blood clots

An analysis of randomized controlled trials indicates that use of the cancer drug bevacizumab is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to an article in the November 19 issue of JAMA, the Journal of the American Medical Association.

18 Nov 2008

Gene study sheds new light on lung cancer

A multi-institution team, funded by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), today reported results of the largest effort to date to chart the genetic changes involved in the most common form of lung cancer, lung adenocarcinoma. The findings should help pave the way for more individualized approaches for detecting and treating the nation's leading cause of cancer deaths.

22 Oct 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

New model predicts whether patients will be free of renal cancer 12 years after initial treatment

A UT Southwestern Medical Center physician and other researchers have developed a unique statistical model that predicts the probability of a patient being cancer free 12 years after initial surgical treatment.

2 Jun 2008

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

Health Discovery receives notice of allowance of U.S. patent application covering kernel selection methods

Health Discovery Corporation has announced that the U.S. Patent and Trademark Office has issued a notice of allowance of HDC's patent application covering methods for selection of kernels, i.e., functions or algorithms that are used to transform input data into a different configuration, known as "feature space", which allows for easier recognition of patterns within the data.

18 Oct 2007